Company Performance Metrics
- Yossi Bornstein: Chairman and Acting CEOPast Role: Trialog Clinical Trials, Founder
Brainose Technologies is a medical company that develops and markets nasal delivery of cannabis-derived therapeutics. The company has developed a nose-to-brain delivery system for cannabis-derived therapeutics for the treatment of central nervous system (CNS) indications. It currently developing a pharmaceutical-grade cannabinoid-based therapy with
a focus on pain management for FDA and CE approval in the U.S. and Europe.
Brainose Technologies state-of-the-art delivery method provides significant advantages over other delivery options, confirming huge commercial preference in this growing arena of the cannabis-derived market. The company unique approach makes use of a patented device platform that improves safety, efficacy and patient compliance and ensures accurate dosing.
Brainose Technologies was founded in January 2017 and is based in Rosh Ha’Ayin, Israel.
